Business Wire

ASSET-VALUE-INVESTORS

29.4.2021 10:29:09 CEST | Business Wire | Press release

Share
Asset Value Investors (AVI) Calls for Shareholder Support to Remove and Replace Symphony International Holdings’ Board of Directors

Asset Value Investors (“AVI”) today launches a new campaign calling on shareholders of Symphony International Holdings Ltd (“SIHL”), a closed-end investment vehicle managed from Singapore and listed on the London Stock Exchange, to help bring about change at the company after years of poor performance. AVI owns a 15.4% stake in SIHL on behalf of institutional clients. Having first invested in 2012, it has now been concluded that a continued approach of constructive private engagement has no prospects of success.

Tom Treanor, Executive Director , Asset Value Investors introduced the new initiative, stating , The poor performance of Symphony International Holdings Ltd (SIHL) has gone on long enough. We have two key aims and we need the support of our fellow shareholders to make them a reality.”

We aim to:

  1. Ensure all shareholders are fully informed as to our concerns regarding the stewardship of SIHL and the independence of the Board, which in our view is inherently conflicted and whose actions have failed to protect shareholder interests ahead of those of the management team;
  2. Gather together sufficient support (30%, including our own 15.4% stake) to requisition an EGM to remove the current directors and replace them with new directors willing and able to properly represent the interests of shareholders. Following their appointment, the new board would be given a mandate to consult widely with shareholders to build a consensus for the optimal path forward to maximise value for the benefit of all shareholders.

SIHL listed in 2007 with an investment objective focussed on growth through consumer-related investments in Asia. Performance has been abject in absolute terms and when measured against market indices or peer funds. Furthermore, SIHL today trades at a discount in excess of 50% to estimated NAV. It is AVI’s view that the substantial discount at which SIHL trades represents the market’s verdict on the Company’s performance track record, investment proposition, its governance, its Manager, and its Board.

A detailed presentation has been published on its dedicated website www.savesymphony.com and analyses key interconnected areas that require urgent action:

  1. Disastrous NAV and Share Price Performance
  2. Misrepresented Performance and Material Non-Disclosure
  3. Persistently Wide Discount to NAV
  4. Manager Compensation dwarfing Shareholder Returns
  5. Conflicted Board
  6. The 2017 Wind-Up Vote That Wasn’t: Shareholder Exit Frustrated
  7. Forced Partial Sale of Minor International investment at Distressed Prices

Link:

ClickThru

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Demand for GP Financing Is Rising, but the Managers Who Need It Most Are Finding It Hardest to Access23.4.2026 10:00:00 CEST | Press release

Corpay Private Markets publishes its fourth Lender Book Report, drawing on proprietary transaction data and live lender appetite tracking across 500+ lenders Corpay Private Markets, formerly Alpha Private Markets, today publishes the fourth edition of its Lender Book Report, focusing on GP financing across private markets. While demand for GP-level liquidity is rising – driven by longer fundraising cycles, slower exit activity, and increasing GP commitment requirements – access to financing is not expanding evenly. That is the central finding of the latest Lender Book Report. Unlike most research in the fund finance sector, which draws on surveys and reflects market sentiment, the Lender Book Report series is built on proprietary data. This edition combines insights from Alpha Match, Corpay Private Markets' lending intelligence platform tracking 500+ active lenders, with anonymised data from recent GP financing transactions. The data reveals a structural gap. Although the number of GP

Pantheon Expands Global Private Wealth Platform with Infrastructure Secondaries Fund Launch23.4.2026 10:00:00 CEST | Press release

Now with new international vehicle, Pantheon offers clients global evergreen access to full suite of private equity, private credit secondaries, and infrastructure secondaries Pantheon bolsters its globally recognized, specialist approach in infrastructure secondaries in the evergreen market with the launch of the Pantheon Global Infrastructure Secondaries Fund (“PGIS”) PGIS will tap the expertise of Pantheon’s $26.9 billion1 institutional infrastructure franchise Fund marks latest in Pantheon’s growing, $15 billion2 global evergreen platform, which now includes semi-liquid evergreen offerings across private equity, private credit secondaries and infrastructure secondaries in the US and internationally3 Pantheon, a leading global private markets investor, today announced the regulatory approval for the Pantheon Global Infrastructure Secondaries Fund (“PGIS”). Domiciled in Luxembourg, the evergreen fund represents a significant milestone in Pantheon’s private wealth strategy and the exp

KAYTUS Unveils MotusAI Enhancements with OpenClaw for Enterprise-Grade AI Agents23.4.2026 09:02:00 CEST | Press release

Providing a high-availability compute foundation for seamless AI agent deployment, greater resource efficiency, and enterprise-grade reliability. KAYTUS, a leading provider in AI infrastructure and liquid cooling solutions, today launched new capabilities in its MotusAI AI DevOps platform to accelerate the deployment of enterprise-grade AI agents. By a streamlined three-step integration with the OpenClaw framework, MotusAI provides the compute infrastructure, resource orchestration, and operational support required to address deployment bottlenecks, and enable AI agents to scale from early-stage experimentation to dependable enterprise use. Key Challenge for Enterprise-Grade AI Agents: Guaranteed Reliability and Performance As the AI landscape transitions from chatbots to AI agents, enterprises are facing a fundamental constraint: the value of even the most advanced large language model (LLM) depends on the stability and performance of the underlying execution infrastructure. At presen

Samsung Epis Holdings Reports First Quarter 2026 Financial Results23.4.2026 08:54:00 CEST | Press release

Samsung Bioepis recorded Q1’26 revenue of KRW 454.9 billion and operating profit of KRW 144.0 billion Samsung Epis Holdings (KRX: 0126Z0), an investment company dedicated to innovations in biopharmaceuticals and biotechnology, today announced its financial results for the first quarter of fiscal year 2026. “Samsung Bioepis delivered solid growth this quarter driven by continued momentum across our biosimilar portfolio," said Kyung-Ah Kim, President and Chief Executive Officer (CEO) of Samsung Epis Holdings. “We are further strengthening our position through new global partnerships and continued portfolio expansion. As we mark the 10th anniversary of the launch of our first biosimilar in Europe, we remain focused on building on our legacy while investing strategically to support long-term growth. We remain committed to delivering sustainable value for our shareholders.” First Quarter 2026 Results On a standalone basis, in the first quarter of 2026, Samsung Bioepis posted a revenue of KR

Galderma Reports Strong Start to the Year, Delivering First Quarter 2026 Net Sales of 1.473 Billion USD, Growing 25.5% at Constant Currency23.4.2026 07:00:00 CEST | Press release

Ad hoc announcement pursuant to Art. 53 LR Galderma Group AG (SIX:GALD), the pure-play dermatology category leader, today announced its sales performance for the first quarter of 2026. Strong start to the year delivering net sales of 1,473 million USD, predominantly driven by volume and complemented by positive price and mix effects, underscoring the continued execution of its unique, growth-driven integrated dermatology strategy. Widespread net sales growth of 25.5% year-on-year at constant currency1,aligned with strong growth performance across geographies and product categories, including Injectable Aesthetics (+13.1%), Dermatological Skincare (+17.0%) and Therapeutic Dermatology (+71.3%). Continued market outperformance, with broad-based growth momentum across the existing portfolio, complemented by differentiated launches and geographic expansion. Demonstrated scientific leadership with new clinical data presented at major congresses, including positive phase II results for nemoli

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye